Compare POOL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POOL | MIRM |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 1997 | 2019 |
| Metric | POOL | MIRM |
|---|---|---|
| Price | $195.61 | $107.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $274.43 | $119.85 |
| AVG Volume (30 Days) | ★ 1.2M | 685.0K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $5,289,396,000.00 | $19,138,000.00 |
| Revenue This Year | $4.30 | $26.22 |
| Revenue Next Year | $3.84 | $22.04 |
| P/E Ratio | $137.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $172.68 | $47.89 |
| 52 Week High | $345.00 | $114.99 |
| Indicator | POOL | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 65.48 |
| Support Level | $174.74 | $87.93 |
| Resistance Level | $250.38 | $114.99 |
| Average True Range (ATR) | 7.66 | 3.92 |
| MACD | 2.07 | 1.37 |
| Stochastic Oscillator | 62.15 | 85.84 |
Pool Corp is a wholesale distributor of swimming pool supplies, equipment, and related leisure products. The company's products include pool pumps, filters, heaters, and cleaners; pool maintenance products like chemicals, supplies, and repair parts; irrigation and landscape maintenance products; and outdoor lighting, grills, outdoor kitchen components, etc. These products are offered through branded distribution networks such as Horizon, SCP, Poolcorp Commercial Aquatics, Sun Wholesale Supply, Superior Pool Products, and NPT. The company's customers include pool builders, pool service companies, retail stores, commercial pool operators, and landscape contractors. Geographically, it generates maximum revenue from the United States, followed by other markets like Europe and Australia.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.